Gamification, prescriptions for fresh produce, and nutrition education have proven successful components to diabetes prevention and treatment. Panelists including Grace E. Shearrer, PhD, will explain how these concepts have been put into action in the real world.

A Sunday symposium will explore evolving evidence for CGM use in pregnancy. Sarit Polsky, MD, MPH, one of the expert panelists, will compare time in range versus conventional fasting and postprandial targets in pregnancy.

Dual agonists of the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) have taken center stage in the treatment of obesity and type 2 diabetes. Experts, including Timo D. Müller, PhD, will explore GLP-1/GIP-mediated energy metabolism.

Carmella Evans-Molina, MD, PhD, and Peter K. Jackson, PhD, presented differing views on whether COVID-19 infection can cause type 1 diabetes in a debate on the opening day of the 84th Scientific Sessions in Orlando.

Diabetes is the leading cause of kidney disease and kidney failure. Panelists including Andrew Advani, BSc, MBChB(Hons), PhD, FRCP(UK), FRCP(Edin), FASN, will explore shifting disease management strategies.

One of the featured panelists, Gretchen Piatt, PhD, MPH, says the fundamental tenets of patient empowerment, including patient-centered care and autonomous decision-making, remain integral to the practice of behavioral diabetes care.

These abstracts focus on health care disparities in diabetes outcomes, showcase research that explores the underlying factors in diabetes disparities, and demonstrate practical interventions that may contribute to eliminating those disparities.

Diabetes is not just an endocrine disease. It is a cardiometabolic disease that benefits from multidisciplinary care. Goutham Rao, MD, and other panelists will discuss an interdisciplinary approach to diabetes care.

This year’s symposium from the premier clinical research journal of the ADA will focus on strategies to facilitate the delivery of guideline-recommended care for type 2 diabetes prevention and management.

The leader of the U.S. Food and Drug Administration (FDA), Robert M. Califf, MD, will address the diabetes professionals gathered in Orlando as part of the Welcome to the 84th ADA Scientific Sessions—Keynote Address and Panel Discussion.